AAO

GB-102 reduces annual injection burden in patients with wAMD

In a Late Breaking Developments session at AAO 2021, Veeral Sheth MD, Director of Clinical Trials, University Retina and Macula Associates, Hinsdale, IL, discussed results from the Phase 2B ALTISSIMO trial, including a 6-month extended observation phase, evaluating GB-102 for the treatment of wet age-related macular degeneration (AMD). GB-102 is...